主要是分享这些本地实验室的服务能力我们还会再结合我们的产品撤走我们的产品规划去增加新的品类去满足更多的客户需求这个是我们目前海外的实验室的考虑另外整个产能上就是 现在这个阶段刚才我在分享的时候也说过就是处于一个旅进设备的一个切换阶段整个海外的整个Nova就是我们原来的Nova 6000和现在的Apple Watch基本上这个Nova 6000就是在海外实验室基本上是退出已经退出的一个状态那我们基本上现在就切到这个Apple WatchApple Watch这个也是目前还在查货阶段嘛基本上这个在这个 一到九月三个季度到现在看的话基本上三个季度看的话基本上也到五成到六成那个水平吧大概是这样的谢谢明白非常清楚我一点没有其他问题了下面有请问8939的三规则进行提问谢谢 - 喂 请问可以听到您的声音吗?- 可以- 您好 我是现场征券的医药研究员乔嘉宁- 然后我这边的话主要是想跟公司请教两个小一点的问题- 一个的话就是我们的比较小型的业务- 就单细胞侧序和质谱这一块大概前三季度的一个业务体量和一个增长情况是什么样的- 然后另外第二个问题的话 其实我们也看到现在国内的话也是因为有江西江州的一些影响的话企业的投融资情况也开始 ...

Revenue and Profit Performance - Revenue for the third quarter reached RMB 522.53 million, a year-on-year increase of 4.68%[2] - Net profit attributable to shareholders of the listed company was RMB 56.53 million, up 12.52% year-on-year[2] - Total revenue for the first three quarters of 2024 reached 1,519,180,271.23 yuan, a 6.3% increase compared to 1,429,077,493.84 yuan in the same period of 2023[12] - Net profit attributable to the parent company's shareholders in the first three quarters of 2024 was 134,455,987.69 yuan, up 7.3% from 125,274,300.39 yuan in the same period of 2023[13] - Revenue for the first three quarters of 2024 reached RMB 782,690,005.45, a 3.1% increase compared to RMB 758,972,944.97 in the same period of 2023[21] - Net profit for the first three quarters of 2024 was RMB 82,183,129.91, a 12% decrease from RMB 93,362,569.63 in the same period of 2023[22] - Sales revenue from goods and services in the first three quarters of 2024 reached 1,439,494,547.64, a slight increase from 1,403,886,793.48 in the same period of 2023[15] - Sales revenue from goods and services in the first three quarters of 2024 was RMB 504,413,959.15, a 32.9% decrease from RMB 751,927,811.58 in the same period of 2023[23] R&D Investment and Expenses - R&D investment for the quarter was RMB 32.27 million, a decrease of 22.34% compared to the same period last year[4] - R&D investment accounted for 6.18% of total revenue, a decrease of 2.15 percentage points year-on-year[4] - R&D expenses for the first three quarters of 2024 decreased by 15.5% to 77,094,646.26 yuan from 91,241,514.74 yuan in the same period of 2023[12] - R&D expenses increased by 24.4% to RMB 51,675,155.49 in the first three quarters of 2024, compared to RMB 41,544,982.76 in the same period of 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 3.48 billion, a decrease of 3.16% compared to the end of the previous year[4] - Equity attributable to shareholders of the listed company was RMB 2.43 billion, down 1.22% from the end of the previous year[4] - Total assets decreased to 3,480,803,196.01 RMB as of September 30, 2024, compared to 3,594,420,954.11 RMB at the end of 2023[10] - Total liabilities as of the end of Q3 2024 were 1,031,170,984.68 yuan, a decrease of 8.0% compared to 1,120,583,995.29 yuan at the end of Q3 2023[11] - The company's total equity attributable to the parent company's shareholders was 2,427,467,254.85 yuan at the end of Q3 2024, a slight decrease of 1.2% from 2,457,457,998.48 yuan at the end of Q3 2023[11] - Total assets as of September 30, 2024, were 2,693,094,271.74, a decrease from 2,790,423,592.94 at the end of 2023[19] - Total liabilities as of September 30, 2024, were 573,206,904.83, down from 587,220,292.68 at the end of 2023[19] - Total assets as of the end of Q3 2024 were RMB 2,693,094,271.74, a 3.5% decrease from RMB 2,790,423,592.94 at the end of Q3 2023[20] - Equity attributable to shareholders as of the end of Q3 2024 was RMB 2,119,887,366.91, a 3.8% decrease from RMB 2,203,203,300.26 at the end of Q3 2023[20] Cash Flow and Liquidity - Cash and cash equivalents decreased to 358,203,095.52 RMB from 704,728,527.91 RMB at the end of 2023[9] - Net cash flow from operating activities in the first three quarters of 2024 was 38,855,244.60, compared to 37,155,098.63 in the same period of 2023[16] - Cash received from investments in the first three quarters of 2024 was 1,728,418,905.84, up from 1,346,812,462.99 in the same period of 2023[16] - Cash paid for investments in the first three quarters of 2024 was 1,816,991,582.58, a decrease from 1,945,405,220.48 in the same period of 2023[16] - Net cash flow from investing activities in the first three quarters of 2024 was -201,744,126.42, an improvement from -675,346,435.49 in the same period of 2023[16] - Net cash flow from financing activities in the first three quarters of 2024 was -175,317,340.10, compared to -11,681,349.21 in the same period of 2023[16] - The company's cash and cash equivalents at the end of September 2024 were 353,516,728.48, down from 691,622,974.60 at the beginning of the year[17] - Operating cash flow for the first three quarters of 2024 was negative RMB 97,968,148.17, a significant decline from positive RMB 204,792,280.07 in the same period of 2023[23] - Investment cash flow for the first three quarters of 2024 was negative RMB 52,490,344.33, an improvement from negative RMB 244,775,672.35 in the same period of 2023[23] - Cash and cash equivalents at the end of Q3 2024 were RMB 70,664,695.55, a 32.3% increase from RMB 53,431,374.21 at the end of Q3 2023[24] Shareholder and Equity Information - The company's largest shareholder, Li Ruiqiang, holds 51.61% of the shares[6] - The company repurchased 11,141,468 shares, representing 2.68% of the total shares outstanding[7] - Basic earnings per share for the quarter were RMB 0.14, an increase of 7.69% year-on-year[4] - Weighted average return on equity (ROE) for the quarter was 2.32%, a decrease of 0.13 percentage points year-on-year[4] - Basic earnings per share for the first three quarters of 2024 were 0.33 yuan, up 6.5% from 0.31 yuan in the same period of 2023[14] - Total comprehensive income for the first three quarters of 2024 was 139,354,190.77 yuan, a decrease of 2.3% compared to 142,659,082.25 yuan in the same period of 2023[14] - Total comprehensive income for the first three quarters of 2024 was RMB 80,243,004.91, a 14.1% decrease from RMB 93,362,569.63 in the same period of 2023[22] Operating Costs and Expenses - Total operating costs for the first three quarters of 2024 were 1,363,364,801.99 yuan, a 4.6% increase compared to 1,302,778,730.53 yuan in the same period of 2023[12] - Sales expenses for the first three quarters of 2024 increased by 11.7% to 298,100,193.95 yuan from 266,907,751.54 yuan in the same period of 2023[12] Non-Recurring Items - Non-recurring gains and losses for the quarter amounted to RMB 10.83 million, primarily driven by financial asset investment gains and government subsidies[5] Inventory and Accounts Receivable - Accounts receivable increased to 743,599,677.50 RMB from 574,150,299.59 RMB at the end of 2023[9] - Inventory decreased to 173,075,253.90 RMB from 181,513,846.76 RMB at the end of 2023[9] - Accounts receivable as of September 30, 2024, were 591,820,078.84, an increase from 378,711,218.34 at the end of 2023[18] Fixed Assets and Contract Liabilities - Fixed assets increased to 706,001,035.78 RMB from 679,881,094.45 RMB at the end of 2023[10] - Contract liabilities decreased to 714,494,420.60 RMB from 754,971,408.46 RMB at the end of 2023[10] Current and Non-Current Assets - Total current assets decreased to 2,399,707,311.01 RMB from 2,519,240,019.22 RMB at the end of 2023[9] - Total non-current assets increased slightly to 1,081,095,885.00 RMB from 1,075,180,934.89 RMB at the end of 2023[10] Accounts Payable - Accounts payable decreased to 134,186,917.52 RMB from 158,972,532.72 RMB at the end of 2023[10]

证券代码：688315 证券简称：诺禾致源 公告编号：2024-048 北京诺禾致源科技股份有限公司 关于 2024 年前三季度计提资产减值准备的公告 北京诺禾致源科技股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召 开第三届董事会第十九次会议、第三届监事会第十七次会议，分别审议通过了《关 于计提资产减值准备的议案》。现将相关事项公告如下： 一、计提资产减值准备情况的概述 根据《企业会计准则》以及公司的会计政策、会计估计的相关规定，为客观、 公允地反映公司截至 2024 年 9 月 30 日的财务状况及 2024 年前三季度的经营成果， 本着谨慎性原则，公司对截至 2024 年 9 月 30 日公司及下属子公司的金融资产、存 货和长期资产等进行了全面充分的评估和分析，对可能发生资产减值损失的相关资 产计提减值准备。 经公司测算，本期计提的减值准备总额约为 2,506.30 万元。具体情况如下表所 示： 单位：万元 | 序号 | 项目 | 年前三季度计提金额 2024 | 备注 | | --- | --- | --- | --- | | 1 | 信用减值损失 | 2,186.54 | 应收 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2024-049 北京诺禾致源科技股份有限公司 第三届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）第三届监事会第十七次 会议（以下简称"本次会议"）于 2024 年 10 月 24 日召开，公司已于 2024 年 10 月 18 日以邮件、电话等方式向公司全体监事发出了会议通知。本次会议由监事 会主席李兴园女士召集并主持，应参加本次监事会会议的监事 3 人，实际参加本 次监事会会议的监事 3 人。会议符合《中华人民共和国公司法》和《北京诺禾致 源科技股份有限公司章程》（以下简称"《公司章程》"）及有关法律法规要求。会 议审议并通过了如下议案： 一、审议并通过了《关于公司<2024 年第三季度报告>的议案》 监事会对公司编制的 2024 年第三季度报告提出如下审核意见： 1、公司 2024 年第三季度报告的编制、审议及保密程序符合法律、法规、 《公司章程》和公司内部管理制度各项规定。 2、公司 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2024-047 2024 年 2 月 5 日，北京诺禾致源科技股份有限公司（以下简称"公司"）召开 第三届董事会第十五次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司使用不低于人民币 8,000 万元（含），不超过人民币 1.6 亿元（含）的自有资金以集中竞价交易方式回购公司股份，用于实施股权激励及员 工持股计划，并将在公司披露股份回购实施结果暨股份变动公告后 3 年内使用完 毕；若未能在规定期限内使用完毕，董事会将依法履行减少注册资本的程序，尚未 使用的已回购股份将被注销。回购股份期限自本次董事会审议通过回购股份方案 之日起 12 个月内，回购价格最高不超过人民币 28.53 元/股。具体内容详见公司于 2024 年 2 月 6 日披露于上海证券交易所网站（www.sse.com.cn）的《北京诺禾致 源科技股份有限公司关于以集中竞价交易方式回购股份方案的公告》（公告编号： 2024-002）。 公司 2023 年年度权益分派实施后，公司以集中竞价交易方式回购股份价格上 限由不超过人民币 28.53 元/股（含）调整为不超 ...

股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688315 证券简称：诺禾致源 公告编号：2024-046 北京诺禾致源科技股份有限公司 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，北京诺禾致源科技股份有限公司（以下简称"公司"或 "诺禾致源"）股东北京致源禾谷投资管理中心(有限合伙（) 以下简称"致源禾谷"） 持有公司 55,039,203 股股份，占公司总股份的 13.22%；北京诺禾禾谷投资管理 中心（有限合伙）（以下简称"诺禾禾谷"）持有公司 12,580,389 股股份，占公司 总股份的 3.02%。上述股份为致源禾谷和诺禾禾谷于公司首次公开发行并上市前 取得的股份，且于 2024 年 4 月 15 日起上市流通。 集中竞价、大宗交易减持计划的实施结果情况 公司于 2024 年 6 月 6 日披露了《北京诺禾致源科技股份有限公司股东减持 股份计划公告》（公告编号：2024-033），致源禾谷和诺禾禾谷计划通过集中竞价、 大宗交易方式减持诺禾致源股份合计不 ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 2024 半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为北京诺 禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"或"上市公司"） 非公开发行 A 股股票的保荐人。根据《证券发行上市保荐业务管理办法》、《上 海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督导职责， 并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2024 年 7 月 29 日对公司进行了现场检查。 （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； （3）查阅公司与控股股东、实际控制人及其关 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2024-045 北京诺禾致源科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次回购股份符合相关法律法规、规范性文件的规定及公司回购股份方案。 源科技股份有限公司关于以集中竞价交易方式回购股份方案的公告》（公告编号： 2024-002）。 公司 2023 年年度权益分派实施后，公司以集中竞价交易方式回购股份价格上 限由不超过人民币 28.53 元/股（含）调整为不超过人民币 28.48 元/股（含）。具体 内容详见公司于 2024 年 5 月 25 日披露于上海证券交易所网站（www.sse.com.cn） 的《北京诺禾致源科技股份有限公司关于 2023 年年度权益分派实施后调整回购股 份价格上限的公告》（公告编号：2024-031）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每 ...

证券研究报告 | 公司动态点评 2024 年 08 月 26 日 诺禾致源（688315.SH） 业绩保持稳健，全球化布局持续 | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------|-------|-------|------------------------------------------|----------| | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | 买入（维持评级） | | | | | | | | | | | | 营业收入（百万元） | 1,926 | 2,002 | 2,251 | 2,595 | 3,113 | | | | 增长率 yoy （ % ） | 3.2 | 4.0 | 12.4 | 15.3 | 20.0 | 股票信息 | | | 归母净利润（百万元） | 177 | 178 | 203 | 236 | 283 | 行业 | 医药 | | 增长 ...

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of RMB 13.48 based on a 2024 PE of 28x [2][10]. Core Insights - In Q2 2024, the company reported revenue of RMB 528 million, a year-on-year growth of 7.94%, and a net profit attributable to shareholders of RMB 51 million, a decrease of 3.66% [8][9]. - For H1 2024, the company achieved revenue of RMB 997 million, reflecting a 7.18% year-on-year increase, with a net profit of RMB 78 million, up 3.86% [8][9]. - The company continues to expand its global presence, having opened a new laboratory in Munich, Germany, as part of its localization strategy [9]. Financial Performance Summary - The company’s revenue for H1 2024 from Mainland China was RMB 496 million, a 6.27% increase, while revenue from Hong Kong, Macau, Taiwan, and overseas regions was RMB 501 million, growing by 8.09% [8][9]. - The gross profit margin (GPM) for H1 2024 was 41.71%, an increase of 0.14 percentage points, while the net profit margin (NPM) was 8.25%, a decrease of 0.20 percentage points [8][9]. - The company’s cash flow from operating activities for H1 2024 was negative RMB 82.34 million, compared to negative RMB 4.51 million in the same period last year [9]. Earnings Forecast - The estimated earnings per share (EPS) for 2024, 2025, and 2026 are RMB 0.48, RMB 0.57, and RMB 0.68, respectively, with net profit growth rates projected at 12.5%, 19.2%, and 19.0% [2][10]. - The company’s revenue is expected to grow from RMB 2,333 million in 2024 to RMB 3,276 million in 2026, with a year-on-year growth rate of 16.5% in 2024 [3][6]. Business Segments - The revenue breakdown for 2024E includes RMB 635.64 million from life sciences basic research services, RMB 269.25 million from medical research and technology services, and RMB 952.58 million from library sequencing platform services [4].